Purchase this article with an account.
Hanan ElShelmani, Michael A. Wride, Tahira Saad, Sweta Rani, David J. Kelly, David Keegan; Identification of Novel Serum MicroRNAs in Age-Related Macular Degeneration. Trans. Vis. Sci. Tech. 2020;9(4):28. doi: https://doi.org/10.1167/tvst.9.4.28.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To identify circulating microRNAs (miRNA) associated with age-related macular degeneration (AMD). Thus differentially expressed serum miRNA could be used as AMD biomarkers.
This study involved total RNA isolation from sera from patients with atrophic AMD (n = 10), neovascular AMD (n = 10), and age- and sex-matched controls (n = 10). A total of 377 miRNAs were coanalyzed using array technologies, and differentially regulated miRNAs were determined. Extensive validation studies (n = 90) of serum from AMD patients and controls confirmed initial results. Total RNA isolation was carried out from sera from patients with atrophic AMD (n = 30), neovascular AMD (n = 30), and controls (n = 30). Fourteen miRNAs from the discovery dataset were coanalyzed using quantitative real-time polymerase chain reaction (qRT-PCR) to validate their presence.
Unsupervised hierarchical clustering indicated that AMD serum specimens have a different miRNA profile to healthy controls. We successfully identified and validated the differentially regulated miRNAs in serum from AMD patients versus controls. The biomarker potential of three miRNAs (miR-126, miR-19a, and miR-410) was confirmed by qRT-PCR, with significantly increased quantities in serum of AMD patients compared with healthy controls.
Increased quantities of miR-126, miR-410, and miR-19a in serum from AMD patients indicate that these miRNAs could potentially serve as diagnostic AMD biomarkers. All three miRNAs significantly correlated with AMD pathogenesis.
The discovery of new AMD miRNA may act as biomarkers in evaluating AMD diagnosis and prognosis.
This PDF is available to Subscribers Only